Document:

exv10w15

Exhibit 10.15

July 5, 2010

Mr. Jonathan Peacock

XXX

Dear Jonathan:

On behalf of Amgen Inc. (Amgen or the Company), I am pleased to offer you the position of Executive
Vice President — Chief Financial Officer, Level 11, reporting to Kevin Sharer. Your salary will
be paid bi-weekly in the amount of $30,769.23, with 26 pay periods in one year.

You will be entitled to a sign-on bonus of $1,000,000.00, less federal and state tax deductions and
other applicable withholdings. This amount will be paid as soon as administratively practicable 30
days after you report to Amgen for full time employment (your Start Date), subject to your
execution of the enclosed “New Hire Bonus Agreement.” If you are not still employed on the
30th day after your Start Date, the bonus will not be considered earned or vested and
will not be prorated.

You will be granted 100,000 restricted stock units, that shall be made effective as of the day that
is two business days after the release of the Company’s 2010 third quarter earnings, which is
expected to fall on October 28, 2010 (the Effective Grant Date), subject to your being actively
employed by Amgen on that date. Upon each applicable vesting date, you will receive a number of
shares of Amgen common stock, $.0001 par value per share (the Common Stock) equal to the number of
restricted stock units that vest, less any shares that are withheld to satisfy applicable taxes.
This grant will vest at a rate of 25% per year for four years, beginning one year from the
Effective Grant Date, contingent upon your acceptance of the grant in accordance with the Company’s
policy and your being actively employed with Amgen through each vesting date.

Restricted stock units will be subject to the terms and conditions set forth in the applicable
grant agreement.

In addition, subject to your being actively employed on the Effective Grant Date, you will be
granted on the Effective Grant Date the option to purchase 175,000 shares of Common Stock at a
price equal to 100% of the Common Stock closing sales price on the Effective Grant Date. This
option shall be a Non-Qualified Stock Option (“NQSO”) . This option shall be vested at a rate of
25% per year for four years, beginning one year from the Effective Grant Date, contingent upon your
acceptance of the grant in accordance with the Company’s policy and your being actively employed
with Amgen through each vesting date. The options will expire ten years from the date of grant.

Stock options will be subject to the terms and conditions set forth in the applicable grant
agreement.

Beginning in 2011 you will be eligible to receive stock options, restricted stock units, and
performance units as part of Amgen’s Long Term Incentive (LTI) program. Grants under the LTI
program are discretionary as approved by Amgen’s Compensation and Management Development Committee
(the Compensation Committee) of the Board of Directors of the Company (the Board).

For the remainder of 2010, you will be eligible to participate in Amgen’s Global Management
Incentive Plan (the GMIP) pursuant to the terms of the GMIP. Your annual target incentive
opportunity will be 80% of your base salary earnings during the plan year. Your actual GMIP bonus
may be more or less

1

 

than this target amount, and may vary based on Company performance, functional unit performance and
management’s assessment of your individual performance and contribution. You must be actively
employed through the last regularly scheduled business day of a performance year to be eligible for
that year’s GMIP bonus. In 2011, management will nominate you for inclusion in the Executive
Incentive Plan (the EIP). The EIP is the annual incentive plan in which officers of the Company at
your level typically participate, and inclusion is determined and approved by the Compensation
Committee during the first quarter of each calendar year. Your annual target incentive opportunity
(80%) will not change as the result of your participation in the EIP.

You are also eligible to participate in the Amgen Nonqualified Deferred Compensation Plan (the DCP)
to voluntarily defer, on a pre-tax basis, a portion of your annual earnings, including base
salaryand/or GMIP bonus. Shortly after commencing your employment at Amgen, you will receive an
enrollment e-mail regarding the DCP plan for Amgen. A Q&A regarding the DCP is enclosed.

You will be eligible to participate in the Amgen Inc. Change in Control Severance Plan as amended
from time to time (the COC), as a Group I Participant according to the terms of the plan, except
with respect to eligibility to receive the 20% Payment thereunder (which payment is equal to 20% of
any amounts payable to a participant which are subject to the golden parachute payment tax under
IRC Section 4999). If upon your termination, you are eligible to receive severance benefits under
the COC and you are also eligible to receive severance benefits from another plan, you will be paid
the greater of the amount from that plan or the amount provided in the COC, but not both amounts.
A copy of the COC is enclosed as Attachment 2.

If, within the first three years of your employment with Amgen, Amgen terminates your employment
without “Cause”, as defined below, you will be entitled to the benefits described in this paragraph
(the Termination Paragraph), provided that you sign a general release in the form furnished to you
by Amgen. The following are such benefits: two (2) years of base salary and your annual target
incentive opportunity (currently 80%) paid in a lump sum as soon as administratively practicable,
but in no event later than March 15 of the year following the year in which Amgen terminates your
employment and (2) if you elect continuation coverage under the Amgen group medical and dental
plans for yourself and your qualified beneficiaries under the Consolidated Omnibus Budget
Reconciliation Act of 1985 (COBRA), Amgen will pay the cost of such coverage until the earlier to
occur of the following: (A) eighteen (18) months following your termination of employment or (B)
the date on which you are no longer eligible for such COBRA coverage. Please note that this
Termination Paragraph does not alter the at-will nature of your employment at Amgen.

For purposes of the Termination Paragraph, “Cause” means (i) unfitness for service, inattention to
or neglect of duties, or incompetence; (ii) dishonesty; (iii) disregard or violation of the
policies or procedures of Amgen; (iv) refusal or failure to follow lawful directions of the
Company; (v) illegal, unethical or immoral conduct; (vi) breach of the attached Amgen Proprietary
Information and Inventions Agreement; or (vii) any other reason set forth in California Labor Code
Section 2924, in all cases, as determined by Amgen.

As an executive at Amgen, you will be eligible for the following: first-class air transportation
while traveling on company business; an annual physical examination; and, reimbursement for up to
$15,000.00 (gross) per year for financial counseling, tax preparation and related services.

You will also have the opportunity to participate in our comprehensive benefits program. Amgen’s
excellent health care plan currently includes medical, dental, and vision coverage for you and your
eligible dependents. Amgen currently pays the major expense for these programs while staff members
share through payroll deductions. Please be advised that in order for you and your dependents to
be eligible for Amgen’s medical coverage you must:

2

 

	1.	 	Report to work at Amgen or another location to which you are required to travel and
perform the regular duties of your employment.
	 
	2.	 	Contact the Amgen Benefits Center at 1-800-97AMGEN, to enroll within 31 days of your
Start Date date.
	 
	3.	 	Meet all other eligibility requirements under the plan.

You will be eligible to participate in the Amgen Retirement and Savings Plan, which is a 401(k)
plan that provides an opportunity for you to save a percentage of your pay (based on Internal
Revenue Service limits) on a tax-deferred basis. Amgen will also contribute to your 401(k) account
to help you save for your future financial goals. These benefits, services and programs are
summarized in the enclosed brochure called “A Guide to Total Rewards at Amgen.”

This offer is contingent upon the Board’s appointment of you as Chief Financial Officer of Amgen.
Further, it is the Company’s expectation that you will immigrate to the U.S. to perform the duties
of your position as Chief Financial Officer at the Company’s headquarters in Thousand Oaks,
California. Additionally, the Company will be performing a background check and will require you
to take a drug test upon your relocation to the United States. It is an expectation of your
employment that the Company receives satisfactory results from both the background check and the
drug test.

Enclosed and included as part of this offer (Attachment 1) is information regarding Amgen’s
Proprietary Information and Inventions Agreement, the Immigration Reform & Control Act, and a
packet of materials entitled “Arbitration of Disputes” which includes a Mutual Agreement to
Arbitrate Claims. Also enclosed and included as part of this offer in Attachment 1 is information
regarding Amgen’s New Staff Member Letter and Certification. This offer is contingent upon you
truthfully and accurately completing the Certification, and returning it to the Company before or
on your first day of employment.

This offer of employment is contingent upon your completing the items described in Attachment 1,
and upon your ability to perform for Amgen all of the duties of your position without restriction
from, or violation of, any enforceable contractual obligations owed to any former employer or
entity for whom you worked or provided service(s).

Also enclosed and included, as part of this offer (Offer Letter Benefit Summary), is information
about the main points of the relocation assistance that Amgen will provide to you to relocate to
the “local area.” Please note that relocation assistance is contingent upon your execution of the
enclosed “New Hire Relocation Agreement” and that relocation benefits are limited to one benefits
package per household.

You will be contacted by a Relocation Counselor to initiate your relocation benefits within 3
business days after receipt of your signed acceptance of this offer and your signed New Hire
Relocation Agreement.

By signing this letter, you understand and agree that your employment with Amgen is at-will.
Therefore, your employment can terminate, with or without cause, and with or without notice, at any
time, at your option or Amgen’s option, and Amgen can terminate or change all other terms and
conditions of your employment, with or without cause, and with or without notice, at any time.
This at-will relationship will remain in effect throughout your employment with either Amgen Inc.
or any of its subsidiaries or affiliates. This letter, and its enclosures, constitutes the entire
agreement, arrangement and understanding between you and Amgen on the nature and terms of your
employment with Amgen, including, but not limited to, the kind, character and existence of your
proposed job duties, the length of time your employment will last, and the compensation you will
receive. This letter, its enclosures, supersedes any prior or contemporaneous agreement,
arrangement or understanding on this subject matter. By executing this letter as provided below,
you expressly acknowledge the termination of any such prior agreement, arrangement or
understanding, except as referenced in this letter and/or its enclosures. Also, by your execution
of this letter, you affirm that no one has made any written or verbal statement that contradicts

3

 

the provisions of this letter or its enclosures. The at-will nature of your employment, as set
forth in this paragraph, can be modified only by a written agreement signed by both Amgen’s Senior
Vice President of Human Resources and you which expressly alters it. This at-will relationship may
not be modified by any oral or implied agreement or by any Company policies, practices or patterns
of conduct.

The complete terms of the plans, programs and policies referenced to in this letter are set forth
in their respective documents, which are maintained by the Company. The Company reserves the right
to amend or terminate any of these plans, programs or policies at any time, in its sole discretion.
In the event of any difference between this offer letter and the provisions of the respective
plan, program or policy document, the respective document will govern.

You have made an excellent impression on the staff at Amgen. We are enthusiastic about the
contribution you can make, and we believe that Amgen can provide you with attractive opportunities
for personal achievement and growth. I look forward to your favorable reply by July
9th, 2010. If you accept our offer, please sign and date the copy of the letter and
return it in the enclosed envelope to our Staffing Department along with the completed and signed
Proprietary Information and Inventions Agreement and the Mutual Agreement to Arbitrate Claims.
Please retain the original offer letter for your records. If you have any questions regarding this
offer, please contact Chip Bell at (805) 447-8912.

Sincerely,

/s/ Kevin Sharer

Kevin Sharer

Chairman of the Board and Chief Executive Officer

CB:cvb

Enclosures

	 	 	 	 	 

	/s/ Jonathan Peacock

	 	July 6, 2010
	 	 
	 	 	 
	Signature of Acceptance

	 	Date	 	 
	 
	 	 	 	 
	September 1, 2010
	 	 	 	 
	 	 	 
	Anticipated Start Date
	 	 	 	 

4

 

ATTACHMENT 1

In order to accept our offer you will be required to:

	 	A)	 	Complete, date and sign the Amgen Proprietary Information and Inventions
Agreement and return it with your signed offer letter.
	 
	 	B)	 	Sign and date the Amgen New Staff Member Letter and Certification and return it
with your signed offer letter.
	 
	 	C)	 	Date and sign the enclosed Mutual Agreement to Arbitrate Claims and return it
with your signed offer letter.
	 
	 	D)	 	You will be required to provide Amgen with proof of your identity and
eligibility for employment per requirements of the Immigration Reform and Control Act
of 1986 within 3 (three) days of hire. Information pertaining to this Act and required
proof are enclosed.

5

 

NEW STAFF MEMBER LETTER AND CERTIFICATION

Welcome to Amgen (the “Company”). The Company has no need to learn and does not want any
proprietary, confidential or trade secret information that belongs to any prior employers. Please
review and comply with the following instructions and policies, and execute the Certification
below.

	 	•	 	Carefully read the Company’s Proprietary Information and Inventions Agreement
(“PIIA”) that you have executed, and make sure that you understand your obligations
under the terms of the PIIA.
	 
	 	•	 	You may not bring any material to the Company from your prior employers in
hard copy, in electronic format or in any other form.
	 
	 	•	 	Prior to commencing any work for the Company, conduct a search of your personal
computer(s), email accounts, and any other electronic storage devices you possess, as
well as any files you maintain in hard copy, for information or materials belonging to
your prior employers. You are instructed to destroy, delete or return any such
information or materials belonging to your prior employers, consistent with any
obligations you have to the prior employers.
	 
	 	•	 	Do not disclose to or provide the Company with any customer lists you
obtained from or during your employment with your prior employers. When interacting
with doctors or other members of the healthcare industry with whom you may have had
contact in connection with any of your prior employment, clearly indicate to such
persons that you are an Amgen staff member, and focus on the Company’s products rather
than using or discussing information related to your prior employment.
	 
	 	•	 	If you have any doubts regarding whether you may take, disclose, upload, access, or
use any information in your possession, you must err on the side of not taking,
disclosing, uploading, accessing or using the information.
	 
	 	•	 	Do not begin any work for the Company before your employment with your
prior employers has officially ended.
	 
	 	•	 	After commencing work for the Company, do not request that any employee of your
prior employers provide you with, or take any other steps to obtain, any information of
your prior employers.
	 
	 	•	 	Under no circumstances are you permitted to connect to a Company computer any
electronic storage device containing information relating to your prior employers.
Likewise, in performing work for the Company, you are not permitted to use, disclose,
access or upload any such information. If you discover that any confidential,
proprietary, or trade secret information of your prior employers has been uploaded to
any Company computer or email system(s), immediately inform Human Resources.
	 
	 	•	 	The Company may monitor and/or conduct an audit of your use of Company computer
systems, and you should not have any expectation of privacy in data sent, stored or
received on any Company systems.

6

 

Disclose and identify below all agreements relating to your current or prior employment that may
affect your eligibility to become employed by and/or to perform work for the Company, including
non-competition agreement(s), agreements relating to the solicitation of employees or customers, or
other restrictive agreements (collectively, “Restrictive Agreements”), regardless of whether you
believe these agreements are enforceable, or apply to your potential employment with the Company,
or have expired, and provide a copy to Human Resources. If “none,” please so indicate. Do not
leave blank.

	 	 	 	 	 
	Name of Agreement	 	Employer	 	Date signed
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 
	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 
	 	 

(Attach additional sheets, if necessary)

	 	•	 	If you are subject to an agreement not to solicit employees of your prior employers,
you should refrain from doing so. If you are contacted by a former colleague about
employment opportunities with the Company, you should refer such inquiries/candidates
to Amgen’s Staffing Department.
	 
	 	•	 	Do not use any email account (including Company email accounts), text messages,
Instant Messaging, or any other method of written communication to store or discuss
information relating to your prior employers or to recruit or solicit employees of your
former employers.
	 
	 	•	 	Immediately inform your Human Resources Business Partner if you are contacted by any
former employer regarding your work for Amgen and/or any non-competition agreements,
agreements that relate to the solicitation of employees or customers, or any other
restrictive agreements you entered into in connection with any previous employment.

CERTIFICATION

I understand that the above list is only a summary and does not purport to include all of my
continuing obligations to the Company. By signing below I certify that I have and will continue to
comply with the above instructions and policies.

I hereby agree that the Company may, at its sole option and discretion contact my prior employer(s)
to determine whether any Restrictive Agreements exist and, if so, their applicable terms. I
acknowledge that the Company may revoke its offer or terminate my employment if it determines in
its reasonable business judgment that I have failed to disclose or am otherwise subject to an
enforceable Restrictive Agreement.

Nothing in this Letter and Certification is intended to alter, or shall have any impact on, my
status as an at-will employee of the Company. In addition to its right to terminate my employment,
the Company shall have the right to suspend me from work without pay during its investigation into
the existence and/or enforceability of any restrictions on my ability to perform work for the
Company.

I agree:

	 	 	 

	/s/ Jonathan Peacock
	 	 
	 

Signature of Staff Member

	 	 
	 
	 	 
	Jonathan Peacock
	 	 
	 

Print Name of Staff Member

	 	 
	 
	 	 
	July 6, 2010
	 	 
	 

Date

	 	 

7

 

AMGEN SIGN ON BONUS AGREEMENT

FOR

NEW HIRE STAFF MEMBERS

I, Jonathan Peacock, agree to accept my new hire bonus payment (“Bonus”) from Amgen on the
following terms.

1. The amount of the Bonus is described in the offer letter (as may be amended) provided
separately to me.

2. The Bonus will generally be paid to me after thirty (30) days following the date on which I
report to Amgen for full time employment with Amgen. If I am not still employed as of the date
the Bonus is to be paid, the Bonus will not be paid either in part or in full.

3. The Bonus is intended to facilitate my acceptance of employment with Amgen. While the Bonus is
provided by Amgen in its business interests as part of its employee recruitment program, I
acknowledge that the Bonus is not reimbursable to me as a matter of law under California Labor Code
section 2802 or any similar statute.

4. Amgen is providing me with the Bonus with the expectation that I will not in the short term
resign my employment. While, as an at-will employee, I am free to resign at any time, I agree to
reimburse Amgen for the gross amount of my Bonus if I resign my employment for any reason within 12
months from the date of receipt of any Bonus monies. I also agree that in the event of such a
resignation, the amount to be reimbursed shall be due in full and payable by me immediately in cash
(i.e., by check, wire transfer, or similar immediate payment) without further notice or demand by
Amgen. Additionally, any Bonus monies that were to be paid at an agreed upon future date but have
not yet been paid are forfeited upon resignation or termination from the company.

5. Generally, a new hire sign on bonus is considered ordinary wage income to the recipient. I
understand that Amgen will report to appropriate federal and state taxing authorities all income
that Amgen considers to be subject to taxation and will withhold appropriate taxes in accordance
with federal and state regulations. I understand that it is my obligation to declare all income
and pay all taxes owed on such income, if any.

6. In the event that I fail to reimburse Amgen for my Bonus as required by this agreement and Amgen
initiates proceedings to recover such Bonus, the prevailing party in such a suit shall be awarded
its reasonable costs and attorney’s fees.

7. I understand that this agreement shall be governed by the law of the State of California.

8. Nothing in this Agreement will be construed as an employment contract or to guarantee me
employment at Amgen for any fixed term. I understand that my employment at Amgen is at will.

9. The provisions of this agreement are severable. If any part is found to be unenforceable, all
other provisions shall remain fully valid and enforceable.

	 	 	 	 
	I agree:	 	Amgen Inc:	 
	 
	 	 	 
	/s/ Jonathan Peacock

	 	/s/ Sara Wasson	 
	 

	 	 	 
	Signature of Staff Member

	 	Signature of Authorized Representative	 
	 
	 	 	 
	Jonathan Peacock

	 	Director Human Resources	 
	 

	 	 	 
	Print Name of Staff Member

	 	Title of Representative	 
	 
	 	 	 
	July 6, 2010

	 	July 19, 2010	 
	 

	 	 	 
	Date

	 	Date	 

8

 

AMGEN RELOCATION AGREEMENT

FOR

NEW HIRE STAFF MEMBERS

I, Jonathan Peacock, agree to accept certain relocation benefits from Amgen on the following
terms.

1. The relocation benefits to be provided to me are outlined in the Amgen Relocation Policy that
applies to staff members at my grade level.

2. I will obtain relocation benefits from Amgen by following the procedures outlined in the Amgen
Relocation Policy that applies to staff members at my grade level.

3. I understand that I may obtain an estimate of my relocation costs from Amgen/Amgen’s
third-party relocation vendor and that the actual cost of my relocation may be more or less than
the estimate I am provided. I further understand that I can obtain detailed information about the
actual services and costs being incurred during my relocation by contacting Amgen/Amgen’s
third-party relocation vendor.

4. The relocation benefits are to facilitate my move as a result of my decision to accept an offer
of employment with Amgen. I acknowledge that the cost of these benefits is not required to be
reimbursed to me as a matter of law under California Labor Code section 2802 or any similar
statute.

5. Amgen provides the relocation benefits with the expectation that I will not in the short term
resign my employment. While, as an at-will employee, I am free to resign at any time, I agree to
reimburse Amgen for the gross amount of the cost of the relocation benefits (according to the
schedule below) if I resign my employment for any reason within 730 days of the date I report to
Amgen for full time employment. Upon my resignation, the amount to be reimbursed shall be
immediately due and payable by me without further notice or demand. The schedule for reimbursement
is as follows:

	 	 	 	 	 
	 	 	
	Days Since Start Date	 	% of Gross Cost of Relocation Benefits to be Reimbursed to Amgen
	0 to 365 days
	 	100	 %	 
	366- 450 days
	 	75	 %	 
	451 - 540 days
	 	50	 %	 
	541 - 730 days
	 	25	 %	 
	Over 730 days
	 	0	 %	 
	 
	 	 

6. I understand that Amgen will report to federal and state taxing agencies all income that Amgen
considers to be subject to taxation. I understand that it is my obligation to declare all income
and pay all taxes owed on such income, if any.

7. In the event that I fail to make a reimbursement required by this agreement and Amgen initiates
proceedings to recover such reimbursement, the prevailing party in such a suit shall be awarded its
reasonable costs and attorney’s fees.

8. I understand that this agreement shall be governed by the law of the State of California.

9. Nothing in this agreement will be construed as an employment contract or to guarantee me
employment at Amgen for any fixed term. I understand that my employment at Amgen is at will. Nor
does this agreement guarantee me reimbursement of any particular relocation expenses. I understand
that reimbursement is governed by the Amgen Relocation Policy and that I must comply with the
procedures in that policy.

10. The provisions of this agreement are severable. If any part is found to be unenforceable, all
other provisions shall remain fully valid and enforceable.

	 	 	 	 
	I agree:	 	Amgen Inc:	 
	 
	 	 	 
	/s/ Jonathan Peacock

	 	/s/ Sara Wasson	 
	 

	 	 	 
	Signature of Staff Member

	 	Signature of Authorized Representative	 
	 
	 	 	 
	Jonathan Peacock

	 	Director Human Resources	 
	 

	 	 	 
	Print Name of Staff Member

	 	Title of Representative	 
	 
	 	 	 
	July 6, 2010

	 	July 19, 2010	 
	 

	 	 	 
	Date

	 	Date	 

9exv10w54

Exhibit 10.54

Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request

for confidential treatment that has been filed with the Securities and Exchange Commission.

AMENDMENT NO. 6

TO THE MASTER SERVICES AGREEMENT

BY AND BETWEEN

AMGEN INC. AND INTERNATIONAL BUSINESS MACHINES CORPORATION

This Amendment Number 6 (“Amendment”) is entered into effective as of September 23, 2010 (the
“Amendment Effective Date”) by and between Amgen Inc. (“Company”) and International Business
Machines Corporation (“Supplier”).

RECITALS

A. Company and Supplier entered into that certain agreement titled “Master Services Agreement”
effective as of October 22, 2008 pursuant to which Supplier is to provide certain information
systems infrastructure related services (the “Original Agreement”).

B. Thereafter, Company and Supplier entered into that certain document titled “Amendment No. 1 to
the Master Services Agreement” dated January 23, 2009, pursuant to which [*].

C. Thereafter, Company and Supplier entered into that certain document titled “Amendment Number 4
to the Master Services Agreement” dated April 1, 2009, pursuant to which [*].

D. Thereafter Company and Supplier entered into that certain document titled “Amendment Number 2 to
the Master Services Agreement” dated July 17, 2009, pursuant to which [*].

E. Thereafter, Company and Supplier entered into that certain document titled “Amendment Number 3
to the Master Services Agreement” dated October 6, 2009, pursuant to which [*].

F. Thereafter, Company and Supplier entered into that certain document titled “Amendment Number 4
to the Master Services Agreement” dated May 1, 2009, pursuant to which [*].

G. Thereafter, Company and Supplier entered into that certain document titled “Amendment Number 5
to the Master Services Agreement” dated December 14, 2009, pursuant to which [*]. The Original
Agreement together with Amendments 1, 2, 3, 4 and 5 shall be referred to herein as the “Agreement.”

H. Company and Supplier desire, and are willing, to amend the Agreement as set forth herein.

NOW THEREFORE, in consideration of the promises and mutual covenants set forth or referenced
herein, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties have reviewed and accepted all referenced material and any
appendices, exhibits

Confidential

Amgen-IBM Amendment #6

Page 1

 

or other attachments hereto and agree to be bound by the terms and conditions
set forth in the Agreement as modified herein as follows:

1. DEFINITIONS

	 	1.1	 	Capitalized Terms. All capitalized terms not defined herein shall have the
meaning ascribed to them in the Agreement. In the event of a conflict between the
capitalized terms defined and set forth in this Amendment and the defined terms of the
Agreement, the definitions set forth in this Amendment shall control.

2. AMENDMENTS TO THE AGREEMENT

The amendments set forth below shall be effective beginning on the Amendment Effective Date,
unless otherwise indicated.

2.1 Master Services Agreement.

2.1.1 The Parties hereby agree to add the following language to the Agreement as a new
second paragraph of Section 13.6 of the Agreement:

For the Company Provided Equipment that Company wishes Supplier to dispose of, Company
represents, warrants and covenants to Supplier: (1) that Company has and will transfer full
legal and beneficial title to all such Company Provided Equipment to Supplier free and
clear of any and all encumbrances, liens, pledges, legal obligations or other restrictions
of any type; and (2) such Company Provided Equipment is not contaminated by any hazardous
or toxic substance or waste that is not integral to the original equipment or otherwise
expected to occur in a normal business environment. Upon receipt of the Company Provided
Equipment designated by Company for disposal by Supplier, Supplier will evaluate each item
and reserves the right to reject such Company Provided Equipment if Company is not in
compliance with any of the representations, warranties or covenants outlined in this
Section 13.6. Supplier will provide written notice to Company of any rejected Company
Provided Equipment within thirty (30) business days of receipt by Supplier. Any Company
Provided Equipment not rejected as provided herein will be deemed accepted. For Company
Provided Equipment accepted by Supplier, Supplier will provide to Company a listing of all
such Company Provided Equipment by serial number. Title to such Company Provided Equipment
will pass to Supplier when accepted by Supplier as outlined in this Section 13.6. Risk of
loss will transfer to Supplier upon receipt of the Company Provided Equipment by Supplier.

2.1.2 The Parties hereby agree to add the following language to the Agreement as a new
Section 23.14(D) of the Agreement:

If applicable to Supplier in performance of the Services, Supplier shall comply with the
employee notice and related obligations found at 29 CFR Part 471, Appendix A to Subpart A,
and to the extent that such notice and related obligations are required by Applicable Law
to be incorporated into the Agreement, they are hereby so incorporated.

[*]

3. GENERAL TERMS

This Amendment may be executed in several counterparts, all of which taken together shall
constitute one single agreement between the Parties. This Amendment, when read in conjunction with
the Agreement (including all exhibits, attachments, and schedules thereto) constitutes the entire
agreement between the Parties with respect to the subject matter of this Amendment and pursuant to
the terms of this Amendment supersedes all prior agreements, whether written or oral, with respect
to the subject matter of this Amendment. Unless any amendment set forth above expressly provides
for a different effective date, as of the Amendment Effective Date, the terms and conditions set
forth in this Amendment shall be deemed a part of the Agreement for all purposes. In the event of
a conflict or inconsistency between the terms and conditions set forth in this Amendment and those
set forth in the Agreement, the terms and conditions of

Confidential

Amgen-IBM Amendment #6

Page 2

 

the Agreement shall control. Except as
amended and supplemented hereby, all of the terms and conditions of the Agreement shall remain and
continue in full force and effect and apply hereto.

IN WITNESS THEREOF, the authorized representatives of the Parties have executed this Amendment to
the Agreement.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

	AMGEN INC.	 	 	 	 	 	INTERNATIONAL BUSINESS MACHINES CORPORATION	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Signature: /s/ Robert E. Kuntz	 	Signature: /s/ John Lydon	 	 	 
	 Name: Robert E. Kuntz
	 	 	 	Name: John Lydon	 	 	 
	Title: Category Manager
	 	 	 	Title: Senior Project Exec	 	 	 
	Date: September 24, 2010
	 	 	 	Date: September 29, 2010	 	 	 

Confidential

Amgen-IBM Amendment #6

Page 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]